论文部分内容阅读
目的探讨可必特、布地奈德氧驱动雾化吸入治疗婴幼儿喘息性疾病的疗效。方法将64例有喘息症状的婴幼儿随机分成治疗组(32例)及对照组(32例),两组均在常规治疗的基础上予治疗组加用可必特、布地奈德氧驱动雾化吸入辅助治疗,对照组常规使用激素。结果治疗组治愈28例(87.5%),好转3例(9.4%),无效1例(3.1%),总有效率96.8%;对照组治愈13例(40.6%),好转12例(37.5%),无效7例(21.8%),总有效率78.1%;两组比较差异具有显著性(P<0.05)。结论用可必特、布地奈德氧驱动雾化吸入辅助治疗婴幼儿喘息性疾病,疗效确切、方法简单、安全,见效快、用药量少,值得临床推广。
Objective To investigate the curative effect of nifedipine and budesonide oxy-driven atomization inhalation in the treatment of infantile asthmatic diseases. Methods Sixty-four infants and young children with wheezing symptoms were randomly divided into treatment group (32 cases) and control group (32 cases). Both groups were treated on the basis of conventional treatment with cortisone, budesonide oxygen-driven fog Inhalation of adjuvant therapy, the control group routine use of hormones. Results The treatment group was cured in 28 cases (87.5%), improved in 3 cases (9.4%), ineffective in 1 case (3.1%), the total effective rate was 96.8%; in the control group, 13 cases (40.6% , 7 cases (21.8%) were ineffective and the total effective rate was 78.1%. There was significant difference between the two groups (P <0.05). Conclusions It is worthy of clinical application to use bupivacaine and budesonide to drive atomized inhalation to treat infantile asthmatic diseases. The curative effect is exact, the method is simple, safe and quick, with less dosage.